---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-022184"
form_type: "8-K"
ticker: "CTXR"
cik: "0001506251"
company_name: "Citius Pharmaceuticals, Inc."
filed_at: "2024-03-13T23:59:59+00:00"
generated_at: "2026-06-04T22:12:32.459248+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Citius Pharma gets Nasdaq bid-price compliance extension to Sept 9, 2024; annual meeting elects directors

## Summary
- Nasdaq granted extension until Sept 9, 2024 to regain $1.00 minimum bid price; stock continues trading under CTXR.
- If compliance not achieved by Sept 9, 2024, Nasdaq will issue delisting notice; company can appeal to hearings panel.
- At March 12 annual meeting, all seven director nominees elected (Leonard Mazur, Myron Holubiak, Suren Dutia, Dr. Eugene Holuka, Dennis McGrath, Robert Smith, Carol Webb).
- Stockholders ratified Wolf & Company as auditor for FY ending Sept 30, 2024 with 77.2M votes for, 2.5M against.
- Company evaluating options to regain bid price compliance; no assurance of success.

## SEC filing metadata
- accession: 0001213900-24-022184
- form_type: 8-K
- ticker: CTXR
- cik: 0001506251
- company_name: Citius Pharmaceuticals, Inc.
- filed_at: 2024-03-13T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01, 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506251/000121390024022184/0001213900-24-022184-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506251/000121390024022184/ea0201715-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-022184
- JSON: https://secwatch.observer/filing/0001213900-24-022184.json
- Plain text: https://secwatch.observer/filing/0001213900-24-022184.txt

## Key facts
- Listing & Compliance Notices
  Citius Pharmaceuticals, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: March 12, 2024, Citius Pharmaceuticals, Inc. (the “Company”) received formal notice that the Nasdaq Stock Market LLC (“Nasdaq”) granted our request for an extension through September 9, 2024 (the “Extension Notice”) to evidence compliance with the $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). If at any time before September 9, 2024, the bid price of our common stock closes at $1.00 per share or more for a minimum of ten consecutive business days, Nasdaq will provide the Company with written co
  evidence_url: https://www.sec.gov/Archives/edgar/data/1506251/000121390024022184/0001213900-24-022184-index.htm
- Shareholder Votes
  Citius Pharmaceuticals, Inc. shareholders approved Ratification of Wolf & Company, P.C. as independent registered public accounting firm for fiscal year ending September 30, 2024 at the 2024-03-12 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2024-03-12
  source text: Also at the meeting, our stockholders ratified the selection of Wolf & Company, P.C. as our independent registered public accounting firm for the fiscal year ending September 30, 2024. The vote for such approval was 77,204,591 shares for, 2,548,248 shares against, 5,613,605 shares abstaining, and no broker non-votes.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1506251/000121390024022184/0001213900-24-022184-index.htm
- Shareholder Votes
  Citius Pharmaceuticals, Inc. shareholders approved Election of seven directors for a one-year term at the 2024-03-12 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2024-03-12
  source text: We held our 2024 annual meeting of stockholders on March 12, 2024. At the meeting, stockholders elected the following seven members to our Board of Directors for a one-year term expiring at the annual meeting of stockholders to be held in 2025 or until their successors are duly elected and qualified, based on the following votes: Nominee For Withheld Broker Non-Votes Leonard Mazur 33,233,815 3,936,260 48,196,369 Myron Holubiak 33,776,316 3,393,759 48,196,369 Suren Dutia 33,496,184 3,673,891 48,196,369 Dr. Eugene Holuka 31,416,676 5,753,399 48,196,369 Dennis M. McGrath 29,156,167 8,013,908 48,196,369 Robert Smith 34,234,323 2,935,752 48,196,369 Carol Webb 33,187,520 3,982,555 48,196,369
  evidence_url: https://www.sec.gov/Archives/edgar/data/1506251/000121390024022184/0001213900-24-022184-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.